Horizon’s Joel White spoke with Axios for its article, “How Trump could weaken Medicare drug pricing negotiations.” The article focuses on how if Donald Trump is re-elected, he could get his shot at brokering Medicare prices for drugs and why it matters.
HGA’s White, spoke about the impact a Trump-appointed Health Secretary could have.
Trump appointees may also try to increase transparency around negotiations and cut the number of dedicated staff at Health and Human Services to “dramatically reduce the amount of money and people working on the program,” added Joel White, a GOP strategist and president of Horizon Government Affairs.